- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Conditions for Administering Bispecific Therapy
Experts explore optimal conditions for effective bispecific therapy in an insightful panel discussion.
EP: 1.Conditions for Administering Bispecific Therapy
EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics
EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration
EP: 4.Pain Points In Bispecific Operationalization
EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy
EP: 6.Optimizing Bispecific Use Through EMR Utilization
EP: 7.Best Practices For Uptake and Use of Bispecific Therapy
EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy
EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions
EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies
EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care
EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies
EP: 13.Managed Care Considerations Within Bispecific Landscape
EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies
EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy
EP: 16.Bispecific Therapies: Current and Future Considerations
The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.
The video discusses considerations for operationalizing bispecific monoclonal antibodies in cancer care. It highlights the importance of having protocols in place for patient monitoring, transition of care, risk evaluation and mitigation strategies programs, management of adverse events like cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, and long-term toxicity monitoring. Key factors include setting patient eligibility criteria, caregiver reliability for adherence, transportation to handle severe adverse effects, and financial considerations for insurance authorizations. As these are continuous therapies, extensive plans must be made to support patients across the entirety of their treatment journey.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
